Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | SGMS2 | Q8NHU3 | 4/20 | 0.60 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL339377 | 0.83 | NPC1 (0.57) | MEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL340956 | 0.82 | KMT2A (0.62) | MEN1KMT2AGAATDP1ALDH1A1 | |
| SCHEMBL339293 | 0.79 | LRRK2 (0.63) | MEN1KMT2ASGMS2LRRK2GAA | |
| SCHEMBL6526624 | 0.78 | MAPK14 (0.65) | MEN1KMT2ASGMS2LRRK2GAA | |
| SCHEMBL21775803 | 0.78 | FOLH1 (0.62) | SGMS2LRRK2TDP1L3MBTL1ALDH1A1 | |
| SCHEMBL21774384 | 0.77 | LRRK2 (0.56) | SGMS2LRRK2GAAL3MBTL1NPC1 | |
| SCHEMBL340260 | 0.77 | LRRK2 (0.65) | MEN1KMT2ASGMS2LRRK2GAA | |
| SCHEMBL875474 | 0.76 | SGMS2 (1.00) | MEN1KMT2ASGMS2GAATDP1 | |
| SCHEMBL27481232 | 0.76 | MEN1 (0.58) | MEN1KMT2ASGMS2LRRK2GAA | |
| SCHEMBL30468871 | 0.76 | SGMS2 (0.67) | MEN1KMT2ASGMS2GAATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3112348-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Tairx, Inc. (TW) | 2017-01-04 | — | — | EP | disclosed |
| US-8524740-B2 | Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives | TAIRX, INC. (TW) | 2013-09-03 | — | — | US | disclosed |
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Efficient Pharma Management Corporate (TW) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | SLC22A8, ABCC8, CYP2C8 | MEN1 2493/4885KMT2A 2015/4885SGMS2 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.